DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 13.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 584,065 shares of the medical device company's stock after purchasing an additional 69,535 shares during the quarter. Envestnet Asset Management Inc. owned about 0.15% of DexCom worth $45,423,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Versant Capital Management Inc acquired a new stake in shares of DexCom in the 4th quarter worth about $25,000. Private Trust Co. NA lifted its holdings in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. TD Private Client Wealth LLC grew its holdings in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares in the last quarter. Larson Financial Group LLC lifted its stake in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in DexCom during the 4th quarter worth $38,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

DexCom stock traded up $1.50 during mid-day trading on Tuesday, hitting $68.89. The stock had a trading volume of 2,750,380 shares, compared to its average volume of 4,188,608. DexCom, Inc. has a one year low of $57.52 and a one year high of $139.24. The firm has a market capitalization of $27.01 billion, a P/E ratio of 48.17, a P/E/G ratio of 2.30 and a beta of 1.50. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The firm's 50 day moving average is $76.49 and its 200 day moving average is $76.68.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, sell-side analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Michael Jon Brown sold 13,000 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the sale, the executive vice president now owns 105,602 shares in the company, valued at $7,432,268.76. This represents a 10.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 105,009 shares of company stock worth $8,044,178. Corporate insiders own 0.30% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on DXCM. Citigroup upped their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Morgan Stanley boosted their price objective on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and raised their target price for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $99.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.